Scalper1 News
Regeneron Pharmaceuticals (REGN) beat analysts’ expectations with its Q4 report Tuesday, sending shares up 2.5% in early trading in the stock market today, though its guidance on main drug Eylea was merely in line with expectations. Sales in the quarter totaled $610 million, up 47% from the year-earlier quarter and $29 million more than analysts’ consensus. Non-GAAP net income rose 52% to $2.24 a share. Thomson Reuters’ estimates are not entirely Scalper1 News
Scalper1 News